Prognostic Value of Inflammatory and Nutritional Biomarkers of Immune Checkpoint Inhibitor Treatment for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Akihiro Sakai; Hiroaki Iijima; Koji Ebisumoto; Mayu Yamauchi; Takanobu Teramura; Aritomo Yamazaki; Takane Watanabe; Toshihide Inagi; Daisuke Maki; Kenji Okami

doi:10.3390/cancers15072021

Cancers (Mar 2023)

Prognostic Value of Inflammatory and Nutritional Biomarkers of Immune Checkpoint Inhibitor Treatment for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Akihiro Sakai,
Hiroaki Iijima,
Koji Ebisumoto,
Mayu Yamauchi,
Takanobu Teramura,
Aritomo Yamazaki,
Takane Watanabe,
Toshihide Inagi,
Daisuke Maki,
Kenji Okami

Affiliations

Akihiro Sakai: Department of Otolaryngology, Head and Neck Surgery, School of Medicine, Tokai University, Isehara 259-1193, Japan
Hiroaki Iijima: Department of Otolaryngology, Head and Neck Surgery, School of Medicine, Tokai University, Isehara 259-1193, Japan
Koji Ebisumoto: Department of Otolaryngology, Head and Neck Surgery, School of Medicine, Tokai University, Isehara 259-1193, Japan
Mayu Yamauchi: Department of Otolaryngology, Head and Neck Surgery, School of Medicine, Tokai University, Isehara 259-1193, Japan
Takanobu Teramura: Department of Otolaryngology, Head and Neck Surgery, School of Medicine, Tokai University, Isehara 259-1193, Japan
Aritomo Yamazaki: Department of Otolaryngology, Head and Neck Surgery, School of Medicine, Tokai University, Isehara 259-1193, Japan
Takane Watanabe: Department of Otolaryngology, Head and Neck Surgery, School of Medicine, Tokai University, Isehara 259-1193, Japan
Toshihide Inagi: Department of Otolaryngology, Head and Neck Surgery, School of Medicine, Tokai University, Isehara 259-1193, Japan
Daisuke Maki: Department of Otolaryngology, Head and Neck Surgery, School of Medicine, Tokai University, Isehara 259-1193, Japan
Kenji Okami: Department of Otolaryngology, Head and Neck Surgery, School of Medicine, Tokai University, Isehara 259-1193, Japan

DOI: https://doi.org/10.3390/cancers15072021
Journal volume & issue: Vol. 15, no. 7
p. 2021

Abstract

Read online

This study aimed to determine the prognostic value of inflammatory and nutritional biomarkers of immune checkpoint inhibitor (ICI) therapy for recurrent or metastatic squamous cell carcinoma of the head and neck (RMHNSCC) and to identify the most useful factor for prognosis assessment. We retrospectively reviewed the medical records of patients with RMHNSCC who received ICI therapy. The response rate for ICI therapy and the relationship between inflammatory and nutritional biomarkers and overall survival were examined. The included biomarkers did not correlate with an objective response rate but were associated with a disease control rate. Univariate analysis showed significant correlations between the serum albumin level, C-reactive protein level, platelet to lymphocyte ratio, neutrophil to lymphocyte ratio, lymphocyte to monocyte ratio (LMR), systemic immune-inflammation index, and controlling the nutritional status score and overall survival; multivariate analysis showed that LMR was significantly correlated with overall survival. LMR was the most important biomarker according to the machine learning model. This study suggests that LMR may be the most useful biomarker for predicting the prognosis of ICI treatment for RMHNSCC.

Published in Cancers

ISSN: 2072-6694 (Online)
Publisher: MDPI AG
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.mdpi.com/journal/cancers/

About the journal

Abstract

Keywords